Instil Bio Inc (TIL) USD0.000001
Instil Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cell therapy pipeline of autologous tumor infiltrating lymphocyte (TIL) therapies for the treatment of patients with cancer. It is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma. It is also developing a class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR) platform. ITIL-168 is an autologous TIL therapy that it is initially developing for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma. Its pipeline also includes ITIL-306, its lead CoStAR-TIL product candidate. ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (FOLR1), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.